Trial · NCT02155309
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
NCT02155309, Phase 2, Phase 3, Terminated, Repurposed Therapeutics, Inc.; results first posted 2018-01-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray. Trials, record NCT02155309. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02155309
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
- NCT number
- NCT02155309
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 63 participants, actual
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Conditions
- Motion Sickness
- Interventions
- Scopolamine, Placebo
- First posted
- 2014-06-04
- Last updated
- 2018-01-17
- Results first posted
- 2018-01-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy: Number of Head Movements During Rotation | 40 min | During rotation, efficacy is measured by the number of head movements subjects are able to make (12 per minute). While seated yaw-axis rotating, a pre-recorded computerized voice informed subjects to make paced head tilts of 30 ̊ to the right and left at a rate of 0.125 Hz (right, center, left, and back to center over 16 seconds). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy: Number of Head Movements During Rotation | 40 min | Number of head tilts | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy: Number of Head Movements During Rotation | Efficacy: Scopolamine and Placebo (Crossover, Double-blind) | Head Tilts: Scopolamine Condition | 222.5 | Standard Deviation 105 | Number of head tilts |
| Efficacy: Number of Head Movements During Rotation | Efficacy: Scopolamine and Placebo (Crossover, Double-blind) | Head Tilts: Placebo Condition | 191.7 | Standard Deviation 95.1 | Number of head tilts |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PK: Scopolamine Only, Open-label | 13 | |
| Overall Study | STARTED | Efficacy: Scopolamine, Then Placebo | 10 | |
| Overall Study | STARTED | Efficacy: Placebo, Then Scopolamine | 13 | |
| Overall Study | COMPLETED | PK: Scopolamine Only, Open-label | 13 | |
| Overall Study | COMPLETED | Efficacy: Scopolamine, Then Placebo | 10 | |
| Overall Study | COMPLETED | Efficacy: Placebo, Then Scopolamine | 12 | |
| Overall Study | NOT COMPLETED | PK: Scopolamine Only, Open-label | 0 | |
| Overall Study | NOT COMPLETED | Efficacy: Scopolamine, Then Placebo | 0 | |
| Overall Study | NOT COMPLETED | Efficacy: Placebo, Then Scopolamine | 1 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nonserious AEs | General disorders | PK: Scopolamine Only, Open-label | 11 | 13 | 42 |
| other | Nonserious AEs | General disorders | Efficacy: Scopolamine (Crossover, Double-blind) | 18 | 23 | 82 |
| other | Nonserious AEs | General disorders | Efficacy: Placebo (Crossover, Double-blind) | 19 | 23 | 65 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PK: Scopolamine Only, Open-label | 0 | 13 |
| Total, all-cause mortality | Efficacy: Scopolamine (Crossover, Double-blind) | 0 | 23 |
| Total, all-cause mortality | Efficacy: Placebo (Crossover, Double-blind) | 0 | 23 |
| Total, other adverse events | PK: Scopolamine Only, Open-label | 11 | 13 |
| Total, other adverse events | Efficacy: Scopolamine (Crossover, Double-blind) | 18 | 23 |
| Total, other adverse events | Efficacy: Placebo (Crossover, Double-blind) | 19 | 23 |
| Total, serious adverse events | PK: Scopolamine Only, Open-label | 0 | 13 |
| Total, serious adverse events | Efficacy: Scopolamine (Crossover, Double-blind) | 0 | 23 |
| Total, serious adverse events | Efficacy: Placebo (Crossover, Double-blind) | 0 | 23 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 11297908 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02155309
GET https://conductscience.org/api/trials/v1/NCT02155309/registered